Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Pfizer's ABRYSVO shows sustained RSV protection in adults

EditorRachael Rajan
Published 02/29/2024, 10:04 PM
Updated 02/29/2024, 10:04 PM
© Reuters.

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE) reported that its respiratory syncytial virus (RSV) vaccine, ABRYSVO®, maintained high efficacy in adults aged 60 and over through a second RSV season. According to the company's ongoing Phase 3 RENOIR trial, the vaccine showed 77.8% efficacy against RSV-associated lower respiratory tract disease with three or more symptoms.

The data, derived from disease surveillance in the Northern and Southern Hemispheres, indicated that the vaccine's protection was consistent for both major RSV subgroups, A and B. After two seasons, ABRYSVO demonstrated an overall efficacy of 81.5% across both subtypes. The vaccine also continued to show efficacy against less severe cases of the disease, with a protection rate of 55.7% after the second season, slightly lower than the 65.1% observed after the first season.

No new adverse events were reported in the second season, and Pfizer plans to continue post-marketing studies to further understand ABRYSVO's safety profile. Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer at Pfizer, highlighted the importance of the vaccine's broad and durable protection against both types of RSV.

The U.S. Food and Drug Administration (FDA) approved ABRYSVO in May 2023 for the prevention of RSV in individuals 60 years of age or older. The vaccine received further approvals for maternal immunization to protect infants against RSV, with recommendations for administration during 32 through 36 weeks of gestation.

Pfizer has initiated additional clinical trials to evaluate the vaccine's efficacy in children at higher risk for RSV disease and adults with underlying medical conditions. The company intends to submit the recent findings to regulatory authorities and aims to publish the data in a peer-reviewed scientific journal.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

RSV is a common and contagious virus that can cause serious respiratory illness, particularly in young infants, older adults, and individuals with chronic medical conditions. Each year in the United States, RSV is responsible for a significant number of hospitalizations and deaths among older adults.

The information presented in this article is based on a press release statement from Pfizer Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.